Karen Gustavson

Associate
Full contact info

Experience

Rasa Raises $30 Million Series C

February 14, 2024

Cooley advised Rasa, a leading generative conversational artificial intelligence platform, on its $30 million Series C financing.

Read more

Related contacts

Matthew Bartus
Partner, San Francisco
Emily Iannarelli
Associate, Palo Alto
Karen Gustavson
Associate, Seattle
Lauren Zeidan
Associate, San Francisco
Rebecca Ross
Special Counsel, Washington, DC
Kristin O'Hanlon
Special Counsel, San Francisco
Caitlin Courtney
Partner, Palo Alto
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Kimia Therapeutics Closes $55 Million Series A

December 19, 2023

Cooley advised Kimia Therapeutics on its $55 million Series A financing. Partner Josh Seidenfeld led the Cooley team advising Kimia Therapeutics, which is a drug discovery platform that uncovers novel biological insights through precision chemistry and machine learning.

Read more

Related contacts

Josh Seidenfeld
Partner, Palo Alto
Karen Gustavson
Associate, Seattle
Rachel Robichaux
Associate, Palo Alto
Phoebe Huang
Associate, Seattle
Meg Begur
Associate, London
Colleen Badgley
Partner, Seattle

Related Practices & Industries

Rani Therapeutics – $73 Million IPO

July 31, 2021

Cooley advised Rani Therapeutics on its $73.3 million initial public offering of 6,666,667 shares of Class A common stock. Rani Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol RANI, is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. Partners Josh Seidenfeld, Mark Weeks, John McKenna and Charlie Kim led the Cooley team.

Related contacts

Josh Seidenfeld
Partner, Palo Alto
Mark Weeks
Partner, Palo Alto
John McKenna
Partner, Palo Alto
Charlie Kim
Partner, San Diego
Marina Remennik
Special Counsel, Palo Alto
Megan Ji
Associate, Seattle
Rachel Lydon
Associate, San Diego
Karen Gustavson
Associate, Seattle

Related Practices & Industries

NVIDIA – $5 Billion Senior Unsecured Notes Offering

June 30, 2021

Cooley advised NVIDIA on its registered debt offering of $5 billion aggregate principal amount of investment grade senior unsecured notes. The offering consisted of $1.25 billion aggregate principal amount of 0.309% notes due 2023; $1.25 billion aggregate principal amount of 0.584% notes due 2024; $1.25 billion aggregate principal amount of 1.550% notes due 2028; and $1.25 billion aggregate principal amount of 2.000% notes due 2031. Partners Michael Tollini, Mischi a Marca, Jason Savich, Eric Jensen and John McKenna led the Cooley team advising NVIDIA.

Read more

Related contacts

Michael Tollini
Partner, Washington, DC
Mischi a Marca
Partner, San Francisco
Jason Savich
Partner, San Francisco
Eric Jensen
Vice Chair, Palo Alto
John McKenna
Partner, Palo Alto
Natalie Karam
Partner, Palo Alto
Milson Yu
Partner, Palo Alto
Karen Gustavson
Associate, Seattle
Annelise Bertrand
Associate, Palo Alto
Kim Merritt
Paralegal Specialist, San Francisco
Timothy Nguyen
Special Counsel, San Francisco
Savannah Harms
Associate, New York
Eileen Marshall
Partner, Washington, DC
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Patrick Gibbs
Partner, Palo Alto
Francis Wheeler
Partner, Colorado

Related Practices & Industries

Cooley advises Pivot Bio on $100M Series C Round

May 4, 2020

Cooley advised California-based agricultural biotech growth company Pivot Bio on its $100 million Series C funding round, co-led by repeat investors Breakthrough Energy Ventures and a global investment company. Pivot Bio has raised $186 million to date and plans to use the funds to scale-up its microbial nitrogen technology that helps farmers boost crop yield and reduce reliance on synthetic nitrogen fertilizer. The funding will also be used to help the company expand internationally. "The strong backing by our Series C investors enables Pivot Bio to redefine the future of fertilizer and provide the world's farmers with a new nitrogen source. Based on remarkable demand, we expect to ramp up from our large current footprint to millions of additional acres in the next growing season." said Karsten Temme, Ph.D., CEO and co-founder of Pivot Bio, in a news release.

Related contacts

Frederick Dorey
Special Counsel, Palo Alto
John Sellers
Partner, Palo Alto
Emily Iannarelli
Associate, Palo Alto
Lauren Creel
Partner, Palo Alto
Chris Holly
Partner, Washington, DC
Judd Lauter
Special Counsel, San Francisco
Karen Gustavson
Associate, Seattle
View more